MASLD and EGIR study groups annual meeting

Pisa 01– 03 December 2025

Scuola Superiore Sant'Anna, Piazza Martiri della Libertà 33, Pisa, Italy
Venue of the Talks: Aula Magna.
Lunch and Coffee Break: Atrio del Roseto and Cortile del Roseto.

DAY 1

13:30 – 14:00 Registration

14.00 – 14.10 Opening Welcome –
Opening Welcome: **Amalia Gastaldelli, Andrea Natali, Michele Emdin, Paola Tognini**

SESSION I
Title: Unraveling the Link between MASLD and Diabetes – Pathophysiology, Risk Factors, and Disease Progression
Chairs *Mina Mitrakou (University of Athens), Luca Valenti (University of Milan)*

INVITED LECTURES

14.10 – 14.40 Type 2 Diabetes- *Stefano Ciardullo, (Università Milano-Bicocca, Italy)*
14.40 – 15.10 Type 1 Diabetes– *Jonathan Mertens, (Antwerp University Hospital, Belgium)*

15.10-16:20 – Abstracts Session

15 – *Early enhancement of oral glucose absorption characterizes MASLD - Domenico Tricò*
38 – *Adipose tissue insulin resistance is a marker and a major driver of severe MASH - Nateneal Beyene*
21 – *The association between adipose tissue dysfunction and MASH severity is mediated by insulin resistance, regardless of BMI - Silvia Sabatini*
31 – *Adipose tissue insulin resistance, not muscle insulin resistance, is associated with impaired metabolic health in humans - Kiana Meshkat*
26 – *Improving Cardiovascular Risk Stratification Through the Derivation and Validation of an Elevated Triglyceride-Glucose Index - Stavros Athanasopoulos*
06 – *Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes - Martina Chiriacò*

16.20 – 17.00 Coffee break

SESSION II
Title: Innovative Therapeutic approaches in cardiometabolic diseases
Chairs Paula Macedo (University of Lisbon)

17.00-18.45 INVITED LECTURES

17.00 – 17.30 Liver-Directed Therapies in MASLD and *MASH - Elisabetta Bugianesi, (University of Torino, Italy)*
17.30 – 18.00 Metabolic treatments for fibrosing MASH - *Lise Lotte Gluud, (University of Copenhagen, Denmark)*
18:00 – 18.30 Towards a Unified Approach: One Therapy for Diabetes, Obesity, and MASLD – *Stefano Del Prato, (University of Pisa & Sant'Anna School of Advanced Studies, Pisa, Italy)*
18.30 – 18:45 Panel discussion

DAY 2

SESSION III
Title: Mitochondria, Metabolism, and Inflammation: Emerging Insights into MASLD and Systemic Metabolic Regulation
Chairs: Luca Valenti (University of Milan, Italy), John Jones (CNC, University of Coimbra, Portugal)

8:30-09:10 Short oral and Invited lectures

41 *– Mitochondrial respiration and morphology are altered in fatty acid induced insulin resistant liver cells - Nina Krako Jakovljevic*
20 *– Sex-dependent hepatic transcriptomic remodeling in a weight cycling mouse model of MASLD - Vanessa Dubois*
22 *– Exploring the role of circadian rhythms in CDKL5 deficiency disorder Maria Grazia Giuliano*
35 *– Dynamic Stress Hyperglycemia Ratio during OGTT Uncovers Metabolic Alterations in Subjects with Hepatic Steatosis - Annmaria Dagostino*
27 *– A Nutritional Challenge Reprograms Microglial Transcriptome and Function via Gut Microbiota–Brain Crosstalk - Alice Miniati*

09.10-10.10 INVITED LECTURES
09.10 – 09.40 Hepatic Inflammation and Fibrosis in MASLD: Mechanisms and Implications - *Sophie Lotersztajn, (Inserm U1149, Paris, France)*
09.40– 10.10 From Steatosis to Fibrosis: The Inflammatory Pathways in MASLD - *Fabio Marra, (University of Firenze, Italy)*

Session IV
Title: Inflammation, Fibrosis, and Cardiometabolic Outcomes in MASLD
Chairs: Daniel Cuthbertson, (University of Liverpool, UK)

10.10 – 10.50 Abstracts Session
36 *– Mind the Liver–Heart Axis in MASLD: MRI-derived extracellular volume fraction mapping reveals subclinical cardiac tissue remodeling - Puria Nabilou*
39 *– Non-invasive liver fibrosis tests as independent predictors of cardiac remodeling - Kaya Esingul*
11 *– Resmetirom treatment and reduction in major adverse cardiovascular events in MASLD: a target trial emulation - Alex E Henney*
05 *– Targeting epigenetic readers rewires the metabolic and inflammatory shift of the vascular–perivascular adipose tissue interface in cardiometabolic disease - Alessandro Mengozzi*

10.50 – 11.20 Coffee break

Session V
Genetics, Metabolism, and Non-Invasive Biomarkers in MASLD: From Molecular Mechanisms to Clinical Translation
Chairs: Lise Lotte Gluud (University of Copenhagen, DK), Domenico Trico' (University of Pisa, Italy)

***11.20-13.00 Abstracts* session**
03 *– PNPLA3 p.I148M variant affects lipid droplets number and composition in patient-derived liver organoids - Elia Casirati*
14 *– A functional genomic framework to elucidate novel causal MASLD genes - Peter Saliba Gustafsson*
19 *– PLIN2 expression in monocytes as a metabolic marker of obesity and MASH - Patrizia Infelise*
32 *– Glucagon and nutrient composition shape postprandial metabolic responses after gastric bypass surgery - Samantha Pezzica*
37 *– Longitudinal interactions between insulin clearance and glucose homeostasis in non-diabetic individuals Carlo Alberto Rossi*
33 *– Genetic markers for prediction of clinical outcomes in metabolic dysfunction-associated steatotic liver disease - Elias Badal Rashu*

12.20-13.00 Short Abstract session

43 *– Comparison of FibroScan© and iLivTouch© for liver stiffness and steatosis assessment in patients with MASLD – Kamela Gjini*

30 *– Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and MASLD - Petralli Giovanni*

23 *– Succinate Modulation as a Biochemical Correlate of Metabolic and Neurobehavioral Changes Associated with Intermittent Fasting in Obesity - Andrea Tognozzi*

18 *– Non-invasive assessment of meal [U-13C] glucose conversion to hepatic cytosolic acetyl-CoA in T2D/MASLD patients using p-amino benzoic acid - João G. Silva*

42 *– Influence of the MBOAT7 rs641738 polymorphism on the prognosis of patients with MASLD and hepatocellular carcinoma - Guariglia Marta*

13.00 – 14.25 Light lunch

SESSION VI
Title: ***Metabolic, Hepatic, and Microbiome Interplay: Mechanisms, Biomarkers, and Imaging Insights***
Chair: Cecilia Morgantini (University of Pisa, Italy)

14.30 – 15.30 INVITED LECTURES

14.30 – 15.00 Functional imaging of gut microbiota and organ metabolism - *Patricia Iozzo (Institute of Clinical Physiology, CNR, Italy)*
1500 – 15.30 Gut Microbiome in MASH: From Dysbiosis to Therapeutic Intervention - *Onno Holleboom (Amsterdam UMC University)*

SESSION VII
Title: Inflammation and Metabolic Crosstalk in Liver and Cardiovascular Disease
Chair Helen Roche (University College Dublin, Ireland), Paola Tognini, (Sant'Anna School of Advanced Studies, Pisa Italy)

15.30 – 16.20 Abstracts Session

16 *– Early-life gut microbiota transplantation in mice has long-lasting effects on liver development - Federica La Rosa*

40 *– Diet-induced induction of hepatic serine/threonine kinase STK38 triggers proinflammation and hepatic lipid accumulation - Kajal Jaswal*

04 *– Parallel exploration of serum and interstitial fluid lipoproteins and inflammatory signatures of atherosclerosis in type 2 diabetes - Jennifer Härdfeldt*

07 *– G6PD as a novel therapeutic target for MASLD-induced HCC - Andrea Caddeo*

16.20 – 17.00 Coffee break

SESSION VIII -
Title: Are we ready for a precision medicine approach?
Chairs: John Petrie (University of Glasgow, UK), Amalia Gastaldelli (Institute of Clinical Physiology, CNR, Italy)

17.00-18.45 INVITED LECTURES

17.00 – 17.30 Metabolic subtypes of MASLD - *Stefano Romeo, (Karolinska University and University of Gothenburg, Sweden).*
17.30 – 18.00 Metabolic Heterogeneity and the Future of Precision Medicine - *Paul Franks, (Lund University, Sweden)*
18:00 – 18:30 Shaping the Future of Precision Medicine in Obesity and Type 2 Diabetes – *Francesco Giorgino, (University of Bari Aldo Moro, Italy)*
18.30 - 18:45 Panel discussion

DAY 3

SESSION IX
Title: Therapeutic Strategies and Clinical Outcomes in Metabolic Liver Disease
Chairs: Amalia Gastaldelli, (Institute of Clinical Physiology, CNR, Italy), Maria Paula Macedo, (Nova University Lisbon, Portugal)

8:30 – 9:10 Short Abstract session

25 *– Mass spectrometry-based untargeted metabolomics in lean patients with MAFLD - Gokcen Basaranoglu*
12 *– Clustering approach from early pregnancy data for predicting gestational diabetes and adverse delivery outcomes - Agnese Piersanti*
29 *– Differential Associations Between Liver Fat and Postprandial Glucose Levels Across Sex and Menopausal Status; The Maastricht Study - Esther J. Kemper*
02 *– Hormone replacement therapy and major adverse liver outcomes in peri-menopausal MASLD patients - Jo Wilson*
34 *– Circulating microRNA signatures as potential biomarkers in diabetic kidney disease phenotypes stratification - Agnese Sgalippa*

9:10 – 09.50 Abstract session

09 *– Sex-specific development of MASH and glucose intolerance in a murine MASH model - Kristiaan Wouters*
13 *– Sugar rationing in the first 1000 days after conception and long-term risk of MASLD - Dan Cuthbertson*
44 *– Targeting endothelial dysfunction with zibotentan/dapagliflozin: effects on kidney and liver health - Phil Ambery*
24 *– M21 small molecule targets TRPA1 to engage GLP-1 biology and reduce fatty–fibrotic liver injury - Giuseppe Daniele*

SESSION X
Title: Organ Dysfunction and Metabolic Diseases
Chairs: Andrea Natali, (University of Pisa, Italy)

09:50-10:50 INVITED LECTURES

09.50 – 10.20 Liver: Glucose Sensing, Insulin Signaling, and Glucotoxicity – *Luca Valenti (University of Milan, Italy)*
10.20 – 10.50 Adipose Tissue Dysfunction as a Driver of Metabolic Diseases – *Sini Heinonen, (University of Helsinki, Finland)*
10.50 – 11.20 Kidney: Novel Insights into Metabolic-Associated Kidney Disease – *Anna Solini, (University of Pisa, Italy)*

11:20 – 11:40 Ceremony AWARD **Michele Emdin, Amalia Gastaldelli and Andrea Natali**
LUBRANO PRIZE
MASLD PRIZE
EGIR PRIZE

11:40 –13.00 Coffee break networking